Merus NV 10-Q quarterly reports

Merus N.V. reports Q3 2025 results, highlighting the pending Genmab acquisition offer, increased R&D spend on key oncology candidates, and a significant net loss, while maintaining a strong cash position into 2028.

Merus N.V. reports increased net losses driven by accelerated R&D for its oncology pipeline, while significantly bolstering its cash reserves to fund operations into 2028.

Merus N.V. reports a net loss of $96.5 million for Q1 2025, alongside increased revenue driven by commercial material sales and collaboration agreements.

Merus N.V., a clinical-stage oncology company, released its third quarter 2024 financial results, highlighting increased operating expenses and a net loss, alongside progress in clinical trials and collaborations.

Merus N.V. reports a net loss of $50 million for the second quarter of 2024, alongside significant advancements in clinical programs and a strong cash position.

Merus N.V., a clinical-stage oncology company, reported a net loss of $34.5 million for the first quarter of 2024, while highlighting progress in its clinical programs and a new collaboration with Gilead.